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Abstract
Background: Traditionally, non-small cell lung cancer is treated as a single disease entity in terms of systemic therapy.
Emerging evidence suggests the major subtypes—adenocarcinoma (AC) and squamous cell carcinoma (SqCC)—respond
differently to therapy. Identification of the molecular differences between these tumor types will have a significant impact in
designing novel therapies that can improve the treatment outcome.
Methods and Findings: We used an integrative genomics approach, combing high-resolution comparative genomic
hybridization and gene expression microarray profiles, to compare AC and SqCC tumors in order to uncover alterations at
the DNA level, with corresponding gene transcription changes, which are selected for during development of lung cancer
subtypes. Through the analysis of multiple independent cohorts of clinical tumor samples (.330), normal lung tissues and
bronchial epithelial cells obtained by bronchial brushing in smokers without lung cancer, we identified the overexpression
of BRF2, a gene on Chromosome 8p12, which is specific for development of SqCC of lung. Genetic activation of BRF2, which
encodes a RNA polymerase III (Pol III) transcription initiation factor, was found to be associated with increased expression of
small nuclear RNAs (snRNAs) that are involved in processes essential for cell growth, such as RNA splicing. Ectopic
expression of BRF2 in human bronchial epithelial cells induced a transformed phenotype and demonstrates downstream
oncogenic effects, whereas RNA interference (RNAi)-mediated knockdown suppressed growth and colony formation of
SqCC cells overexpressing BRF2, but not AC cells. Frequent activation of BRF2 in .35% preinvasive bronchial carcinoma in
situ, as well as in dysplastic lesions, provides evidence that BRF2 expression is an early event in cancer development of this
cell lineage.
Conclusions: This is the first study, to our knowledge, to show that the focal amplification of a gene in Chromosome 8p12,
plays a key role in squamous cell lineage specificity of the disease. Our data suggest that genetic activation of BRF2
represents a unique mechanism of SqCC lung tumorigenesis through the increase of Pol III-mediated transcription. It can
serve as a marker for lung SqCC and may provide a novel target for therapy.
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Lung cancer is the most common cause of cancer deaths
worldwide [1,2]. It is projected that by 2020, lung cancer will be
the fifth most lethal entity among all diseases [3]. Improvement in
survival has been very modest. Less than 16% of lung cancer
patients survive 5 y or more [2], owing to late diagnosis and a
paucity of effective therapies.
Squamous cell carcinoma (SqCC) and adenocarcinoma (AC)
are the predominant non-small cell lung cancer (NSCLC) cell
types [4]. Currently, they are regarded as a single disease entity in
terms of systemic therapy. There is increasing evidence that AC
and SqCC respond differently to therapy [5,6]. The differences in
therapeutic response may be related to the specific cell lineages
from which they develop. Biological differences that segregate with
lineage may also lead to differences in progression and response to
therapies [7]. Specific genes and their respective pathways may
lead to carcinogenesis only when disrupted in permissive
conditions [8]. For example, a gene may have oncogenic
properties when overexpressed in basal cells in the central airway
compartment because it supports growth under these conditions;
however, the same gene may have no effect on Clara cells in the
lung periphery. Recent studies using transgeneic mouse models
support this theory. For example, in murine models with KRAS
mutations [9–12], although all airway epithelial cells contained
this mutation, only adenomatous hyperplastic lesions—precursors
to AC—developed in the peripheral lung in these mice, suggesting
that only particular gene alterations in specific cell types in a
certain local environment or niche can lead to the development of
the individual lung cancer subtypes.
Cell lineage may also have a dramatic effect on the
manifestation of genetic alterations during the development of
lung cancer subtypes, as only those promoting a specific malignant
phenotype will be selected and maintained [7,13]. DNA
amplification and subsequent overexpression is a predominant
mechanism of oncogene activation in epithelial cancers, including
those of lung origin [14,15]. The subsistence of a DNA amplicon is
thought to result from selection of genes within the amplified
region that promote tumor growth [14]. Thus, the specific
requirements for tumorigenesis in different cell lineages may
therefore be associated with selection of different amplicons. Copy
number increase of 8p12-8p11.21 is one of the most frequent focal
changes in NSCLC occurring in ,9%–35% of cases, with
amplification present in ,3%–8% of cases in the literature, a
frequency rivaling those of established NSCLC oncogenes such as
MYC (,6%) and EGFR (,3%) [16,17]. In this study, we sought to
determine the lineage specificity of the 8p amplicon in order to
discover novel oncogene(s) restricted to tumorigenesis, in partic-
ular NSCLC cell types.
Methods
Ethics Statement
All patient samples were collected under informed patient
consent and anonymized as approved by the University of British
Columbia - British Columbia Cancer Agency Research Ethics
Board (REB number H04-60060).
Tumor Samples
Formalin-fixed, paraffin-embedded, and fresh-frozen tissues
were collected from St. Paul’s Hospital, Vancouver General
Hospital and Princess Margaret Hospital following approval by
the Research Ethics Boards. Formalin-fixed paraffin-embedded
lung carcinoma in situ (CIS) samples were collected by
fluorescence bronchoscopy-directed biopsies at the British Colum-
bia Cancer Agency. Hematoxylin and eosin-stained sections of
each sample were examined by a lung pathologist to select regions
of interest for microdissection to ensure .70% tumor cell content.
DNA was isolated using standard procedure with proteinase K
digestion followed by phenol-chloroform extraction as previously
described [18].
Tiling-Path Array Comparative Genomic Hybridization
Array hybridization was performed as previously described
[19–21]. Briefly, equal amounts (200–400 ng) of sample and single
male reference genomic DNA were differentially labeled and
hybridized to SMRT array v.2 (BCCRC Array Laboratory,
Vancouver, BC) previously described to give optimal genome
coverage [22,23].
Hybridized arrays were imaged using a charge-coupled device
(CCD) camera system and analyzed using SoftWoRx Tracker
Spot Analysis software (Applied Precision). Systematic biases
(intensity, spatial, plate, and background biases) were removed
from all array data files using a stepwise normalization procedure
as previously described [15,24]. SeeGH software was used to
combine replicates and visualize all data as log2 ratio plots [25,26].
All replicate spots with a standard deviation above 0.075 or signal-
to-noise ratios below three were removed from further analysis.
The clones were then positioned on the basis of the human March
2006 (hg18) genome assembly. Genomic imbalances (gains and
losses) within each sample were identified using aCGH-Smooth
[27] with lambda and breakpoint per chromosome settings at 6.75
and 100, respectively, as previously described [21]. The resulting
frequency of alteration was then determined for each lung cancer
cell type as described previously [21]. High-level amplifications
were determined using an algorithm previously described with the
log2 threshold set at .0.6 for tumors and .0.8 for CIS cases
(because of different levels of cell heterogeneity) [15]. Regions
were only scored as amplified if two or more consecutive array
elements met these criteria. All array comparative genomic
hybridization (CGH) data are available on the System for
Integrative Genomic Microarray Analysis (SIGMA) Web site at
http://sigma.bccrc.ca/.
Comparison of Cell Type Alteration Frequencies
Regions of differential copy number alteration between AC
and SqCC genomes were identified as follows. Each array
element was scored as 1, gain/amplification; 0, neutral/
retention; or 21, loss/deleted, for each individual sample.
Values for elements filtered on the basis of quality control
criteria were inferred by using neighbouring clones within
10 Mb. Probes were then aggregated into genomic regions if
the similarity in copy number status between adjacent clones was
at least 90% across all samples from the same cell type. The
occurrence of copy number gain/amplification, loss/deletion,
and retention at each locus was then compared between AC and
SqCC datasets using the Fisher exact test. Testing was perform-
ed using the R statistical computing environment on a 362
contingency table as previously described, generating a p-value
for each clone [21]. A Benjamini-Hochberg multiple hypothesis
testing correction based on the number of distinct regions was
applied and resulting p-values #0.01 were considered significant.
Adjacent regions within 1 Mb that matched both the direction of
copy number difference and statistical significance were then
m e r g e d .F i n a l l y ,r e g i o n sh a dt ob ea l t e r e di n.20% of samples
in a group and the difference between groups .10% to be
considered.
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47 fresh-frozen lung tumors were obtained from Vancouver
General Hospital as described above. Microdissection of tumor
cells was performed and total RNA was isolated using RNeasy
Mini kits (QIAGEN Inc.). Samples along with universal reference
RNA were labeled and hybridized to a custom Agilent Whole
Genome Oligonucleotide microarray according to the manufac-
ture’s protocols. The resulting expression data were processed and
normalized using Rosetta Resolver software. Affymetrix U133 Plus
2 expression data for 111 NSCLC tumors were downloaded from
the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/
geo/, accession number GSE3141) and normalized using Micro-
array Suite (MAS) 5.0 [28]. A summary containing the number of
samples analyzed and corresponding platform is presented in
Table S1.
Gene Expression Microarray Analysis of Normal Bronchial
Epithelial Cells
RNA was obtained from exfoliated bronchial cells of 67 lung
cancer–free individuals obtained during fluorescence bronchosco-
py [29]. All individuals were either current or former smokers
without lung cancer. Expression profiles were generated for all
cases using the Affymetrix U133 Plus 2 platform and normalized
using MAS 5.0.
Statistical Analysis of Gene Expression Data
Gene expression probes were mapped to March 2006 (hg18)
genomic coordinates and those within the regions of copy number
difference between the cell types on Chromosome arm 8p were
determined. Comparisons between expression levels for AC and
SqCC tumors as well as SqCC tumors and normal bronchial cells
were performed using the Mann-Whitney U test and computed
with the ranksum function in MATLAB. As the direction of gene
expression difference was predicted to match the direction of copy
number difference, one-tailed p-values were calculated. A
Benjamini-Hochberg multiple hypothesis testing correction was
applied on the basis of the total number of gene expression probes
analyzed. Probes with a corrected p-value #0.01 were considered
significant. If multiple probes mapped to the same gene, the one
with the lowest p-value (Agilent data) or with maximum intensity
across the data (Affymetrix) was used.
Integration of Genetic and Gene Expression Data
To integrate gene expression with copy number data, two
methods were used. First, a 10-kb moving average was generated
using the normalized log2 array CGH ratios for each sample with
copy number and expression. These values were subsequently
standardized using a Z-transformation for each sample throughout
the whole genome in order to facilitate better comparisons across
the sample set. An average Z-score was then calculated using the
values corresponding to the genomic intervals spanning each of
the genes of interest on Chromosome 8p. Finally, a nonparametric
Spearman correlation coefficient was calculated using the Z-scores
for copy number and log10 ratios for gene expression across all
samples of interest. The corresponding p-value representing the
statistical significance of a positive correlation was calculated and a
Benjamini-Hochberg multiple hypothesis testing correction ap-
plied as described above. For the second method, the copy number
status was determined by aCGH-Smooth as described above and
mapped to genes of interest from clones using genomic coordinates
from the UCSC Genome Browser (hg18). The gene expression
levels for all genes were then compared between samples with copy
number gain/amplification against samples that were copy
number neutral using the Mann-Whitney U test [15]. An
association was deemed significant if the Benjamini-Hochberg
corrected p-value #0.05 and the median and mean gene
expression in the samples with gain/amplification were higher
than those samples that were copy number neutral. Again, as the
direction of gene expression difference was predicted to match the
direction of copy number difference, one-tailed p-values were
calculated.
Reverse Transcriptase PCR Analysis of Transcription
Levels in Clinical Tumor Samples
Quantitative reverse transcriptase (RT)-PCR was performed on
SDS7900HT (Applied Biosystems) using SYBR Green and the
DDCt method with RPS13 expression levels used as reference for
normalization. Primers used were: BRF2_F: GTGAAGCTCC-
TGGGACTGGAT, BRF2_R: GTATTTGGCTGGCACAGA-
AGG, RPS13F: GTTGCTGTTCGAAAGCATCTTG, and
RPS13R: AATATCGAGCCAAACGGTGAA. Associations be-
tween BRF2 expression and clinicopathological features were
evaluated by the Wilcoxon test. Breakdown of samples used are
provided in Table S1.
Cell Lines and Culture Conditions
NSCLC cell lines H520, H1395, and H2347 were purchased
from American Type Culture Collection (ATCC). Cells were
maintained in RPMI-1640 medium (Invitrogen) supplemented
with 10% fetal bovine serum (Invitrogen). The HBEC3-KT
immortalized normal human bronchial epithelial cell (HBEC) line
was established by introducing mouse Cdk4 and hTERT into
normal HBECs obtained from a 65-y-old woman without cancer
[30]. The HBEC3-KT53 line was established by stably knocking
down p53 in the original cell line, HBEC3-KT [31]. These two
parental lines were used to overexpress BRF2 via the pMSCV
vector (see below). All HBEC3 cell lines were cultured in K-SFM
(Invitrogen) medium containing 50 mg/ml bovine pituitary extract
(Invitrogen) and 5 ng/ml EGF (Invitrogen).
TaqMan Analysis of Transcript Levels in Cancer Cell Lines
5 mg micrograms of total RNA isolated from cultured cells
(H2122, H2347, HCC193, H1395, H2009, H1993, HCC4006,
HCC2279, H2087, HCC78, HCC461, HCC1195, H1819,
H1648, HCC366, H3255, HCC2450, HCC15, HCC95, and
H520) was converted to cDNA using an ABI High Capacity
cDNA Archive kit (Applied Biosystems). An aliquot of 100 ng of
cDNA was used for each real-time PCR reaction. TaqMan
(Applied Biosystems) gene expression assays: BRF2
(Hs00217757_m1) and 18s rRNA (Hs99999901_s1) were per-
formed using standard TaqMan reagents and protocols on a
Applied Biosystems 7500 Fast Real-Time PCR system (Applied
Biosystems). The DDCt method was used for expression
quantification using the average cycle threshold for 18S rRNA
to normalize gene expression levels between samples [21]. Cycle
thresholds for the primers were then compared between the
individual cell lines and a pooled normal lung cDNA reference
sample generated from Human Lung Total RNA (AM7968,
Ambion) to identify the fold change represented.
Western Blot Analysis of Protein Levels
Cells were washed twice with cold PBS and lysed in the
presence of protease inhibitors. Each cleared lysate was diluted
and boiled for electrophoresis and transferred to polyvinylidene
membrane [31]. Membranes preblocked with 3% bovine serum
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with primary antibodies against BRF2 (Abcam, 1:500 dilution) for
1 h at room temperature. After three washes in PBST, the
membranes were incubated with horseradish-peroxidase-conju-
gated donkey anti-goat polyclonal antibody (Abcam, 1:2,000
dilution) for 45 min at room temperature. After three PBST
washes, antibody binding was visualized by enhanced chemilumi-
nescence (GE Healthcare). Subsequently, the bound antibodies
were stripped from the membranes with a buffer containing
62.5 mM Tris-HCl, (pH 6.7), 2% SDS and b-mercaptoethanol
and reprobed with monoclonal antibody to beta-actin (Abcam,
1:6,000) to confirm equal sample loading.
Northern Blot Analysis of Pol III Transcript Levels
Briefly, total RNA was isolated from cell lines using TRIzol
reagent (Invitrogen) and 4 mg was resolved on an 8% UreaGel
denaturing gradient gel as per manufacturer’s instructions
(National Diagnostics). The gel was then equilibrated in 0.56
TBE for 15 min and RNA was capillary transferred to positively
charged nylon membrane using 0.56 TBE according to the
protocol described by Sambrook and Russell [32]. RNA was
bound to the membrane by UV-crosslinking with 120 J UV light
using a Stratalinker (Stratagene). The blot was then prehybridized
at 45uC for 30 min using DIG Easy hybridization buffer (Roche),
and 50 pmol of DIG labeled30-mer oligonucleotide probe was
then added. Specific probe sequences were as follows: 5S rRNA,
59- CCTGCTTAGCTTCCGAGATCAGACGAGATC-39;U 6
small nuclear RNA (snRNA), 59- CTTGCGCAGGGGCCAT-
GCTAATCTTCTCTG-39; 7SK snRNA, 59-CGTCCTCTTCG-
ACCGAGCGCGCAGCTTCGG-39. Hybridization proceeded
for 16–20 h and blots were washed two times for 15 min at room
temperature in 26SSC, 1% SDS followed by a 15-min wash in
the same buffer at 45uC. Further washes and luminescence
detection was performed using the DIG Wash and Block Buffer set
and the DIG Luminescent Detection kit following the manufac-
turer’s instructions (Roche). Blots were then exposed to Lumi-Film
(Roche) and developed to image.
RNAi Knockdown
For RNA interference (RNAi) experiments, two methods were
employed. For the first method, lentiviral short hairpin RNAs
(shRNA) vectors targeted against BRF2 were purchased from
Open Biosystems. Briefly, individual lentiviruses, each containing
a single pLKO plasmid construct coding an shRNA targeted for
BRF2, were prepared by transfecting 293T cells with the
packaging plasmids VSVG and d8.91 and the shRNA plasmids
using TransIT-LT1 transfection reagent (Mirus). Virus containing
empty pLKO vector served as a control. Virus supernatant was
collected from the transfected 293T cells each day for 3
consecutive days post-transfection. H520 cells were infected at
50% confluency, using 1 ml of each respective virus. After 48 h,
cells were selected with 2.5 mg/ml puromycin. Selection was
continued until all nontransfected cells were dead. Stably
transfected cell lines were maintained in growth media supple-
mented with 2.5 mg/ml of puromycin. Sequence details for BRF2-
1 (TRCN0000016128) and BRF2-2 (TRCN0000016129) can be
found on the Open Biosystems Web site (www.openbiosystems.
com).
For the second method, ON-TARGETplus SMARTpool small
interfering RNAs (siRNAs) targeting BRF2 along with a negative
control (ON-TARGETplus siCONTROL nontargeting siRNA
pool) were obtained from Dharmacon. H520 and H1395 cells
were subcultured at a ratio of 1:3 or 1:6 using 0.25% tryspin-
EDTA (Gibco). Transfection efficiency was optimized using
siGLO Green Transfection Indicator (Dharmacon). For the
transfection experiments, cells were seeded in 24-well culture
plates at 60,000 cells/ml 24 h before transfection. Cells were
transfected at a final concentration of 100 nM siRNA using
Lipofectamine RNAiMAX (Invitrogen) according to the manu-
facturer’s instructions. The cells were then incubated at 37uC for
24 h before RNA analysis, 48 h for protein, and 72 h for MTT
assays. For both shRNA and siRNA experiments, BRF2 expression
levels for multiple independent knockdowns were determined by
qRT-PCR as described above and scaled relative to the average of
the control treated cells (6standard error measure [SEM]).
Cell Proliferation Assays
The 3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bro-
mide (MTT) assay (Trevigen) was used to determine the status of
cell proliferation in both shRNA and siRNA experiments
according to the manufacturer’s instructions. For siRNA exper-
iments, exponentially growing cells were diluted to a concentration
of 313,000 cells/ml in RPMI-1640 with 10% FBS, seeded in
triplicate in 96-well plates and incubated at 37uC for 4 h. The cells
were then treated with 10 ml of MTT reagent for 4 h before
adding 100 ml of detergent reagent to solubilize the formazan
precipitate. The reaction product was then quantified by
measuring absorbance at 570 nm with reference to 650 nm using
an EMax plate reader (Molecular Devices). The mean 6SEM
absorbance values for experiments from three independent
transfections were normalized to the average of the respective
controls.
For shRNA experiments, 4,000 cells for each condition were
seeded in triplicate for each time point in 96-well plates and
treated with MTT as described above at 24, 72, and 96 h. The
absorbance reading for blank (media) wells was subtracted from
the mean absorbance readings for each time point and plotted
(6SEM) to quantify cell proliferation. Replicate experiments were
performed and a representative experiment is shown.
Soft Agar Anchorage-Independent Growth Assay
The H520 stably transfected pLKO vector control and shRNA
BRF2 gene knockdown cell lines were used in the colony formation
assay. Single cell suspensions were prepared in growth media
supplemented with 20% fetal bovine serum (Invitrogen), 2.5 mg/
ml puromycin, 0.1% penicillin-streptomycin (Invitrogen), and
0.3% low-melting point agarose (Invitrogen), resulting in a final
concentration of 1,000 cells/ml. 1 ml of cell suspension (1,000
cells) was plated onto an equal volume of supplemented media
with a 0.5% low-melting point agarose concentration. Supple-
mented media lacking cells was plated as a negative control. Each
cell line was seeded in triplicate in 12-well plates and cultured for
14 d at 37uC, after which colonies were counted and the mean
6SEM were normalized to the average of the control. Replicate
experiments were performed and a representative experiment is
shown.
Construction of the BRF2 Expression Vector
The BRF2 sequence from the pBRF2-HORF construct (Invitro-
gen) was cloned into the retroviral vector pMSCV-hygro (Clontech)
and sequenced. This construct was named pMSCV-BRF2. The
pMSCV-BRF2 construct and the vector alone (pMSCV) were then
transfected into the Pheonix Ampho retroviral packaging cell line
(Orbigen) according to manufacturer’s protocols. Subsequent
infections into HBEC3-KT and HBEC3-KT53 were performed
and plasmid-containing cells were selected by treating with 20 mg/
ml of hygromycin for 10 d. This step resulted in the generation of
four stable cell lines: HBEC3-KT-pMSCV-BRF2, HBEC3-KT-
BRF2 Activation in Lung Cancer
PLoS Medicine | www.plosmedicine.org 4 July 2010 | Volume 7 | Issue 7 | e1000315pMSCV (vector control), HBEC3-KT53-pMSCV-BRF2, and
HBEC3-KT53-pMSCV (vector control).
In Vitro Cell Growth Assays
Growth curves were determined for each of the six HBEC cell
lines by culturing 1,000 cells in triplicate in 12-well plates and
counting on the third, sixth, eighth, and tenth day. The average
6SEM for each line is reported. Replicate experiments were
performed and a representative experiment is shown.
Statistical Analysis of Functional Assays
For all cell model assays, p-values were calculated using the
Student’s t test when comparing two conditions and ANOVA
when comparing three. All calculations were performed with
MATLAB software and one-tailed p-value #0.05 was considered
significant.
Immunohistochemistry
Slides were deparaffinized using xylene and rehydrated through an
ethanol series to water. Antigen retrieval was performed using a
decloaking chamber at 15 psi for 20 min in sodium citrate buffer
(pH 6.0). Endogenous peroxidase enzyme activity was blocked using
3% H2O2 in methanol for 30 min at room temperature. Slides were
washed in 1% PBS and then blocked using 10% skim milk for 6 h at
room temperature. Slides were incubated for 16 h at 4uCw i t ha
1:200 dilution of goat polyclonal anti-BRF2 primary antibody
(Abcam), followed by incubation with a donkey anti-goat biotinylated
secondary antibody (Santa Cruz Biotechnology). Normal goat IgG
was used as negative control (Santa Cruz Biotechnology). Detection
was accomplished using DAB (ImmunoCruz staining system, Santa
Cruz Biotechnology). Slides were then counterstained using hema-
toxylin, and the area within the diagnostic area was scored by three
independent observers on the basis of the following criteria: 0, no
p o s i t i v es t a i n i n g ;1 ,2 5 %p o s i t i v ec e l l s ;2 ,5 0 %p o s i t i v ec e l l s ;3 ,7 5 %
positive cells; and 4, 100% positive cells. Conflicting scores were
resolved by choosing the value consistent between two observers or
the average of all three varying scores.
Significance Analysis of Microarrays
Using the 111 NSCLC samples in the dataset by Bild et al.
(Table S1) [28], samples were sorted by highest to lowest
expression for BRF2 on the basis of the probe with the highest
average intensity across the dataset [28]. Differential gene
expression analysis using significance analysis of microarrays
(SAM) [33] was performed using the ten samples with highest
BRF2 expression against the ten samples with lowest BRF2
expression. A q-value threshold of #0.05 was used to identify
differentially expressed genes associated with high BRF2
expression.
Functional Assessment of BRF2-Associated Genes
Functional analyses were generated through the use of Ingenuity
Pathways Analysis (Ingenuity Systems) as previously described [15].
Functional Analysis identified the biological functions that were most
significant to the dataset. Fisher exact test was used to calculate a p-
value determining the probability that each biological function
assigned to the dataset is due to chance alone.
Results
A Focal Region on 8p Is Preferentially Amplified in SqCC
We compared the 8p chromosome arm of 161 microdissected
NSCLC tumors—103 AC and 58 SqCC (Table S1, sample set
1a)—by tiling resolution array CGH [22]. After hybridization
experiments, genomic profiles were normalized and subjected to a
smoothing algorithm in order to computationally define regions of
copy number gain and loss along the entire length of Chromosome
arm 8p [21]. Individual samples were then grouped by their
corresponding cell type, and probes were aggregated into regions
on the basis of similar copy number status. The resulting frequency
of alteration for each region along the arm was compared between
cell types using the Fisher exact test to identify regions of copy
number disparity, and the resulting p-values were corrected for
multiple comparisons with a cut-off of #0.01 considered
significant (Methods). Although the telomeric portion of 8p was
frequently lost in both AC and SqCC cell types, two regions
spanning a total of 5.65 Mbp at 8p12–8p11.21 were found to be
frequently gained specifically in SqCC (Figure 1a and 1b; Table
S2). Copy number increase of focal regions at 8p12–p11.21 was
found in up to 40% of SqCC tumors, while DNA loss was the most
prevalent event in AC (,39%). In addition, high-level amplifica-
tion (log2 ratio .0.6) was present in ,12% of SqCC samples
(seven out of 58) demonstrating the preferential selection for this
alteration in tumors of this cell lineage. The increased incidence of
8p amplification in comparison to previous reports is attributed to
analyzing the cell types as distinct groups, as opposed to
combining all the NSCLC cell types as a single entity. In addition,
the small sample sizes of previous studies may also have limited the
detection of specific disruptions unique to each cell type to just
extremely high frequency events, such as the gain of Chromosome
3q [17,34,35]. These results indicate that gain/amplification of
8p12–8p11.21 is restricted to SqCC and occurs far more
frequently than previously thought, highlighting the importance
of considering cell lineage in genomic studies of malignancies from
the same tissue site.
BRF2 Gene Expression Drives Selection of the 8p
Amplicon in Lung SqCC
The cell type dependent pattern of 8p amplification raised the
possibility that a lineage-specific oncogene may be driving the
preferential selection of this amplicon in SqCC. Such a gene
should display five fundamental properties each translating into its
own testable hypothesis. First, increased expression would be
restricted to SqCC tumors mirroring the specificity of DNA
amplification (hypothesis 1). Second, as the target of the amplicon,
expression would be higher in SqCC tumors with gain/
amplification than those without (hypothesis 2). Third, expression
should be significantly higher in SqCC tumors than normal
bronchial epithelial cells; that is, the gene should be activated in
cancerous and not normal tissue (hypothesis 3). Fourth, the gene
should have oncogenic potential and provide a growth and/or
survival advantage to cells when overexpressed (hypothesis 4).
Lastly, if necessary for initiating tumorigenesis, amplification
should occur early in tumor development and therefore be present
in lung SqCC precursor lesions (hypothesis 5).
To test the first hypothesis, we generated gene expression
microarray profilesfor a subset of 47 tumors(34 AC,13 SqCC) with
sufficient amounts of material that were also analyzed by array
CGH in order to integrate genetic and gene expression information
(Table S1, sample set 1b). In total, 62 probes corresponding to 44
unique genes mapped to within the alteration boundaries (Table
S2). To identify lineage-restricted genes, we compared the
expression levels for all probes between the AC and SqCC samples.
Since we predicted candidate genes to be overexpressed in SqCC, a
one-tailed Mann-Whitney U test was used with Benjamini-
Hochberg corrected p-values #0.01 considered significant. Ten
unique genes meeting these criteria were uncovered from this
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the AC and SqCC tumors (Figure 1c; Table S3).
After identifying these SqCC specific genes, we next aimed to
ensure that amplification is responsible for their differential
expression, as these will be candidate targets driving amplicon
selection (hypothesis 2). For this purpose, we utilized two
complementary approaches. First, a nonparametric Spearman
correlation coefficient was calculated for each gene using Z-
transformed copy number ratios and log10 gene expression ratios
(Methods). Five of the ten genes (LSM1, BRF2, ASH2L, TM2D2,
and WHSC1L1) had a correlation coefficient of .0.75 and a
corrected p-value (representing the statistical significance of a
positive correlation) of ,0.01 and were further considered as
candidates (Table S3 for all values). The second approach involved
the comparison of expression levels between SqCC tumors with
gene dosage increase (gain/amplification) and those with neutral
copy number status (Methods). Of the five genes with a positive
association between copy number and expression, only three
(LSM1, BRF2, and ASH2L) also showed significantly elevated
transcript levels specifically in SqCC samples with gain or
amplification and were therefore determined to be regulated by
copy number (Table S3). qRT-PCR analysis of BRF2 (the most
likely target gene, see below) confirmed the microarray results
(Figure S1; Table S4). Importantly, none of these genes
demonstrated a correlation between copy number and expression
in AC, reinforcing the specificity of this alteration to SqCC.
Figure 1. Chromosome 8p amplification in NSCLC is restricted to the SqCC lineage. (A) Frequency of gain/amplification along
Chromosome arm 8p is depicted for 103 AC (red) and 58 SqCC clinical tumor specimens (blue). (B) The significance of copy number disparity (inverse
p-value) between AC and SqCC cell type groups is depicted for 8p. Solid black lines represent regions considered statistically different (p#0.01),
whereas dashed lines are not. (C) Relative expression for genes within regions of copy number difference, which were also expressed at significantly
higher levels in SqCC (n=13) compared to AC (n=34) tumors (p#0.01). The color scale ranges from black (low expression) to white (high expression).
doi:10.1371/journal.pmed.1000315.g001
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amplification, a candidate oncogene should only be expressed at
elevated levels in cancerous, and not normal, tissues [36].
Therefore, to test the third hypothesis, we analyzed the RNA
levels of these three genes in an independent panel of 53 SqCC
lung tumors and 67 samples of exfoliated bronchial cells from
cancer-free individuals generated using the Affymetrix U133 Plus
2 platform (Table S1, sample sets 2 and 3). Strikingly, only BRF2
was aberrantly expressed (.2-fold, p,1.0610
28) in cancerous
tissues identifying it as the sole gene passing the three main criteria
of a candidate lineage-specific oncogene described above (Figure 2;
Table S3). To further confirm these observations, a third,
independent sample set consisting of 118 NSCLC tumors and
39 non-neoplastic lung tissues (Table S1, sample set 4) was
analyzed for BRF2 expression by qRT-PCR (Methods). Consistent
with the microarray results, expression of BRF2 in primary tumors
was significantly higher than that in the non-neoplasia tissues
(p,0.001) with overexpression more common in SqCC than AC
(p=0.03), supporting our findings.
Taken together, results from testing the first three hypotheses
clearly demonstrate that BRF2 is the driver gene of the 8p
amplicon and identify it as a candidate lineage-specific oncogene
in SqCC. Previous studies investigating this amplified region in
NSCLC have proposed FGFR1 and WHSC1L1 as potential
oncogenes [17,37]. However, we ruled out FGFR1 as a possible
target as it was not differentially expressed between AC and
SqCC, and as such, was excluded from further analysis. This
conclusion is in agreement with a study by Tonon et al. that
suggested WHSC1L1 as the more likely amplification target in
NSCLC [17]. Although we demonstrated that WHSC1L1
expression was restricted to SqCC and correlated with increased
gene dosage, it was not significantly higher in samples with gain/
amplification or different between normal and cancerous cells
(p=0.12, fold change=1.3), and therefore, also discounted.
BRF2 Contributes to SqCC Tumorigenesis by Regulating
Cell Growth and Proliferation through the Increase of
Polymerase III Activity
BRF2 encodes a subunit of a transcription initiation complex
responsible for RNA polymerase III (Pol III)-mediated transcrip-
tion [38,39]. Pol III transcribes a limited set of genes that encode
nontranslated RNAs including 5S rRNA, tRNA, 7SL RNA, and
U6 RNA, which are essential for protein synthesis and RNA
processing [40]. Because these processes are fundamental
determinates of the capacity of a cell to grow, increased activity
of Pol III is often observed during cancer development [41].
Indeed, transformed cells express elevated levels of Pol III
transcripts, and inhibition of these transcripts limits cell growth
and proliferation [42]. It has been proposed that deregulation of
Pol III in transformed cells can occur through three different
mechanisms: release from cellular repressors, direct activation by
oncogenes, and overexpression of transcription factors [40]. In
normal cells where growth is tightly controlled, tumor suppressors
including RB, p53, and PTEN repress Pol III transcription
[43,44]. Inactivation of these genes or activation of oncogenes
such as MYC and ERK reverse this process [42,44,45]. Interest-
ingly, the majority of these genes are mutated in lung cancer,
representing a potential mechanism of increasing Pol III activity,
and subsequently, cell growth potential during tumorigenesis.
Transcription factors, however, are often the limiting components
of Pol III-mediated transcription and elevated levels of these
components have been observed in numerous cancer types [41].
Recently, the overexpression of another Pol III transcription factor
BRF1 has been shown to increase Pol III-mediated transcription,
resulting in the transformation of cells in vitro and tumor formation
in vivo [46,47]. A study by Marshall et al. was the first to implicate
Pol III deregulation as a causative factor in cancer formation [46];
however, no studies have been reported to date of activating
mutations in Pol III subunits or associated transcription factors in
tumors. Therefore, we hypothesized that the amplification and
overexpression of BRF2 may contribute to lung SqCC tumor-
igenesis by contributing to increased cell growth and proliferation,
representing a novel alternative mechanism of increasing Pol III
transcription in cancer.
To test this hypothesis (hypothesis 4), we performed comple-
mentary loss and gain of function in vitro experiments using lung
cancer cell lines and immortalized HBEC lines, respectively.
Twenty NSCLC cell lines (16 AC and 4 SqCC) previously
analyzed by array CGH were assayed for BRF2 expression by
qRT-PCR (Methods). Mirroring the findings from the clinical
tumor specimens, BRF2 expression was strongly correlated with
gene dosage with the two cell lines with amplification (HCC95 and
H520) displaying the highest transcript levels (Figure S2; Table
S5). In addition, both these lines were derived from SqCC samples
and no AC cell lines contained amplification, re-enforcing the
lineage specificity of BRF2 activation. To determine the effect of
BRF2 overexpression on BRF2 protein levels, three cell lines were
selected for Western blot analysis: a SqCC with amplification
(H520), an AC with neutral copy number (H1395), and an AC
with loss (H2347) (Figure 3a). Consistent with a role in
tumorigenesis, high protein levels were only found in H520.
To determine if increased BRF2 levels lead to higher Pol III
activity, we performed Northern blot analysis to assess the
expression of Pol III-mediated transcripts. BRF2 is specifically
Figure 2. BRF2 is a lineage-specific oncogene targeted by
amplification in SqCC. (A) Comparison of BRF2 mRNA expression
values for AC (n=34) and SqCC (n=13) tumors (p=0.0056). Box-plots
depict the median group expression (red line), the 25th and 75th
percentiles (blue box), and the limits of 95% of samples for each group
(outside lines) with values for all other samples represented by red
crosses. Expression values for all plots are in arbitrary log10 units. (B)
Spearman’s correlation of Z-transformed array CGH copy number ratios
and expression values for BRF2 in 13 SqCC tumors (correlation
coefficient=0.87). Each diamond represents an individual sample. (C)
Comparison of BRF2 expression between SqCC tumors with neutral
copy number status (n=4) and SqCC tumors with gain/amplification
(n=6)(p=0.048). (D) Difference in BRF2 expression levels between 67
exfoliated bronchial cell samples from cancer-free patients and 53
SqCC tumors from an independent sample set (p,1.0610
28).
doi:10.1371/journal.pmed.1000315.g002
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promoters, which are responsible for the expression of snRNA
genes, two of the best characterized of which are U6 and 7SK
[48–50]. This finding is in contrast to type 1 and type 2 Pol III
promoters (gene internal), which require BRF1 for transcription
and are involved in the expression of 5S rRNA and tRNA genes,
respectively [48,50]. Thus, we hypothesized that BRF2 activation
would lead to an increase only in type 3 transcripts and not those
regulated by BRF1. As expected, assessment of transcript levels in
the lung cancer lines showed drastically higher levels of both U6
and 7SK relative to 5S loading control in H520 cells compared to
H1395 and H2347 cells, confirming increased BRF2-dependent
Pol III transcription upon BRF2 activation (Figure 3a). Further-
more, U6 levels were decreased upon knockdown of BRF2
expression in H520 cells using an shRNA construct (Figure S3).
These results match those of a recent study, which showed that
BRF2 protein levels correlate with U6 promoter activity [51].
These data suggest that increased BRF2 levels are sufficient to
increase Pol III activity, demonstrating the downstream mecha-
nistic effect of gene amplification.
To assess the functional significance of BRF2 amplification and
overexpression on SqCC development, RNAi-mediated knock-
down was performed in H520 cells. Expression of two different
shRNAs) targeting BRF2 substantially reduced transcript levels
(Figure 3b) and significantly decreased cell proliferation compared
to a negative vector control (Figure 3c). In addition, knockdown of
BRF2 expression significantly reduced the ability of these cells to
grow in an anchorage-independent manner as measured by colony
formation in soft agar (Figure 3d). Similar results on cell
proliferation were observed with BRF2 siRNA pool transfection
of H520 cells (Figure 3e). In contrast, siRNA knockdown of an AC
cell line without BRF2 amplification and overexpression, H1395,
did not diminish cell proliferation and resulted in an increase in
proliferation relative to transfection with a nontargeting control
siRNA pool (Figure 3e). How knockdown of BRF2 could lead to an
increase in cell proliferation in this context remains unclear and
warrants further investigation. Lastly, to further confirm the
specificity of this effect to cell lines with amplification, we also
performed knockdown experiments in two SqCC cell lines
(HCC15 and HCC2450) without BRF2 amplification (Figure
S4). As expected, no significant decrease in proliferation was seen
in HCC15 or HCC2450 upon BRF2 inhibition. These results
demonstrate a crucial role for BRF2 in contributing to the
sustained cellular proliferation and survival of SqCC tumors with
gene activation and highlight its cell type specific oncogenic
potential in lung cancer.
To further validate its tumorigenic properties, we performed
complimentary experiments by overexpressing BRF2 by stable
transduction of immortalized HBEC lines (Figure S5) and
measured cell growth compared to vector-expressing controls.
HBEC lines are immortalized without the use of viral oncopro-
teins, have minimal genetic changes, and do not exhibit a
transformed phenotype [30,31]. In addition, since they express
epithelial markers and morphology and can differentiate into
mature airway cells, they represent an attractive model for testing
the importance of specific gene alteration found in the initiation of
epithelium-derived lung cancer [30,31]. Strikingly, the introduc-
tion of BRF2 alone resulted in a modest but significant increase in
cellular growth and saturation density, further supporting a
tumorigenic role for this gene (Figure 3f). Furthermore, as p53 is
Figure 3. BRF2 activation contributes to cell growth and proliferation. (A) Concordance between BRF2 copy number (array CGH), expression
(qRT-PCR), protein (immunoblot) levels, and Pol III transcript levels (northern blot) in H520, H1395, and H2347 NSCLC cell lines. (B) Decrease in BRF2
mRNA levels in H520 cells expressing shRNAs targeting BRF2 relative to those expressing a negative vector control (mean 6 SEM of triplicate
samples). (C) BRF2 knockdown results in decreased cell proliferation in H520 cells with amplification and overexpression as measured by MTT assay
relative to vector control (mean 6 SEM of triplicate samples). (D) BRF2 knockdown reduces colony growth of H520 cells in soft-agar relative to vector
control (mean 6 SEM of triplicate samples). (E) siRNA transfection results in decreased cell proliferation as measured by the MTT assay in H520 SqCC
cells but not H1395 AC cells relative to nontargeting siRNA control (mean 6 SEM of triplicate experiments). Increased saturation density in both (F)
BRF2 expressing HBEC and (G) BRF2 and p53RNAi expressing HBEC compared to their respective controls (mean 6 SEM of triplicate samples).
*, p,0.05; **, p,0.01; ***, p,0.001 (Student’s t test; compared to control).
doi:10.1371/journal.pmed.1000315.g003
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Pol III-mediated transcription, we sought to investigate the impact
of BRF2 overexpression in conjunction with p53 silencing on
HBEC growth. Interestingly, the combination of these two
alterations enhanced cell growth greater than each alteration
alone (p=2.36610
25), suggesting a synergistic role for these
alterations in promoting proliferation (Figure 3g). Taken together,
our results demonstrate that BRF2 overexpression plays a key role
in regulating cell growth and proliferation, confirming the
functional significance of BRF2 gene amplification in SqCC.
BRF2 Activation Is an Early Event in SqCC Development
The cell type restricted pattern of activation coupled with its
transformation potential strongly implicates BRF2 as a lineage-
specific oncogene in lung SqCC. SqCC carcinogenesis is thought
to be a multistep process that involves the transformation of
normal mucosa though a continuous range of precursor lesions up
to CIS before invasive cancer and finally metastasis [52].
However, since most studies focus on clinically evident tumors,
little is known about the molecular events preceding the
development of lung cancer and the underlying basis of
carcinogenesis. Unlike low grade dysplastic lung lesions that rarely
progress, the majority of CIS cases will become invasive cancer
[52]. Therefore, we hypothesized that critical alterations necessary
for disease progression would be evident in preinvasive CIS lesions
and persist in invasive tumors. To determine if BRF2 activation
occurs early in SqCC development (hypothesis 5), we analyzed
gene dosage in a panel of 20 CIS lesions (Table S1, sample set 5)
obtained by autofluorescence bronchoscopy (Methods). Remark-
ably, array CGH revealed BRF2 copy number increases in the
majority of CIS cases (Figure 4a) with 35% (seven out of 20)
demonstrating high-level amplification (log2 ratio .0.8; Figure 4b).
WHSC1L1 and FGFR1 were only amplified five times (five out of
20) and once (one out of 20), respectively, further excluding these
genes as primary driver genes of the amplicon (Figure 4b and 4c).
To confirm that amplification results in increased expression of
BRF2 in preinvasive lesions, we performed immunohistochemistry
(IHC) on a CIS sample (CIS2) with amplification (Figure 4c). As
expected, BRF2 expression was elevated in CIS epithelia in this
sample in comparison to normal epithelia from the same patient
(Figure 4d). Strong BRF2 expression was also observed in
additional CIS cases with lower levels in earlier stages of neoplastic
progression (mild, moderate, and severe dysplasia) and little or no
staining in benign lesions (hyperplasia and metaplasia), confirming
that gene activation is an early event in SqCC development
(Figure 5). Interestingly, the only benign lesion in which BRF2
expression was observed was obtained from a patient that had also
developed CIS (Figure 5). The high frequency of activation in
preinvasive lesions suggests that BRF2 plays a critical role in the
development of SqCC through the increase of cell growth
potential. Since patient survival can be significantly improved if
the lesions are detected and treated at their preinvasive stage, the
Figure 4. Amplification and overexpression of BRF2 in preinvasive SqCC lesions. (A) Frequent copy number increase of Chromosome arm
8p in 20 bronchial CIS lesions. Samples are ordered in columns and ordered by genomic position along 8p. The color scale ranges from white (neutral
copy number, N) to black (amplification, Amp). Data from representative normal lung (N) and SqCC tumor samples (T) are displayed to the left and
right of the CIS cases respectively. (B) Amplification score along Chromosome 8p for the 20 CIS cases. Regions of amplification were defined for each
case and summarized across the group to determine the incidence of occurrence. Dashed lines represent the positions of BRF2, WHSC1LC, and FGFR1
from top to bottom respectively. (C) Array CGH copy number profiles for two individual CIS cases with 8p amplification. Each black dot represents an
array element ordered by genomic position. Those shifted to the left of the middle line (N) have decreased copy number (Del), whereas those shifted
to the right have increased copy number (Amp). Dashed lines represent the positions of the three genes as in (B). The region highlighted in orange
represents the region of high-level amplification in each sample. The amplicon in CIS1 includes only BRF2 with WHSC1L1 and FGFR1 outside or
spanning the boundaries while the amplicon in CIS2 contains all three genes. (D) Immunostaining of CIS2 with anti-BRF2 polyclonal antibody revealed
elevated staining in CIS epithelia compared with normal from the same tissue section.
doi:10.1371/journal.pmed.1000315.g004
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invasive SqCC is of vital clinical importance [52,53]. Our finding
that BRF2 is a lineage-specific oncogene amplified early in SqCC
development, and not expressed in normal lung tissue, represents a
critical step in understanding the development of SqCC, and
represents a promising target for therapeutic intervention.
Increased RNA Processing Is Associated with BRF2
Overexpression
To identify other genes and functions that may be associated
with BRF2-mediated initiation of tumorigenesis, we performed
significance analysis of microarrays (SAM) on a panel of 111
NSCLC tumors (Table S1, sample set 2), followed by gene
enrichment analysis using ingenuity pathway assist (IPA) (Meth-
ods). This analysis revealed 86 genes, which were significantly
increased (78) or decreased (8) (false discovery rate ,5%) in
tumors with the highest BRF2 expression (Table S6). IPA analysis
revealed enrichment for genes with diverse biological functions
including RNA post-transcriptional modification, gene expression,
cell cycle, and cancer (Table S7). The identification of RNA post-
transcriptional modification as the most significantly affected
function (p=1.7610
20624.73610
202, the two significance values
refer to a range of specific subfunctions) was significant, as this is
one of the main roles of Pol III-related transcripts as stated above.
The genes related to this function, which are increased in
expression, include FBL, CPSF6, RRP9, SNRPA, SFRS10, CSTF2T,
LSM1, and CPSF3, and are involved in the modification,
polyadenylation, and processing of both mRNA and rRNA. Since
these are fundamental processes necessary for proper protein
production and therefore cell growth, upregulation of these
components may be associated with the increased proliferative
capacity of SqCC cells upon BRF2 activation. However, the exact
nature of this association is currently unknown and future studies
will be needed to understand the mechanism responsible for
BRF2-induced cell growth in SqCC.
Interestingly, as shown above, BRF2 activation leads to
increased transcription from type 3 Pol III promoters that are
involved in the transcription of snRNA genes including U6 and
7SK [49,50]. snRNAs are responsible for a range of regulatory
functions, including the alteration of gene expression and a
potential role for snRNAs in the genomic instability of cancer that
has been proposed [54]. In particular, U6 snRNA forms the
catalytic core of the spliceosome [55]. The spliceosome performs
the splicing of precursor mRNA in eukaryotic cells, removing
introns and joining exons. This process is tightly regulated during
growth and development and aberrant splicing has been linked to
numerous human diseases, including cancer [56]. In fact, many
oncogenes demonstrate alternative splicing patterns associated
with neoplasia, and splicing regulatory factor expression levels
have been shown to increase during cancer progression. Strikingly,
many of the genes we identified as being associated with increased
BRF2 expression, including SNRPA and SFRS10, are known to
interact with snRNAs including U6 in the spliceosome complex. In
addition, SNAPC5, which encodes a member of the snRNA-
activating complex that is required in conjunction with BRF2 to
initiate transcription from snRNA promoters [57], was also found
to be increased in samples with high BRF2 expression. Taken
together, our data suggest that BRF2-mediated increase of U6 as
well as other splicing regulatory factors may contribute to
oncogenesis in SqCC with 8p amplification. Future studies of
the role BRF2 overexpression plays in spliceosome function will
yield insight into this potential function, and its role in the
neoplastic transformation of lung epithelium to SqCC.
Association of BRF2 with Clinical-Pathological and
Genomic Features
Lastly, to investigate the potential clinical significance of BRF2
activation in patients with lung SqCC and better characterize this
subgroup of tumors, we next sought to determine the association
between 8p amplification and clinical-pathological and genetic
features. For this purpose, we expanded our sample set to include
92 SqCC tumors with well-annotated clinical information that
were analyzed by tiling-path array CGH. Overall, increase of
BRF2 copy number was found in 43% of the expanded dataset, in
concordance with the original frequency of alteration. No
associations were found between age, gender, smoking status, or
stage and BRF2 amplification in our dataset. Furthermore, no
significant associations between the level of BRF2 expression and
patient survival were seen in two independent datasets (Figure S6).
However, SqCC tumors with and without BRF2 activation showed
a unique genome-wide spectrum of DNA amplifications, suggest-
ing that different genetic pathways may be involved in their
development (Table S8). Assessment of other clinical and genetic
features—for example response to therapy and mutation events—
will be necessary in the future to further explore the characteristics
of SqCC patients harboring BRF2 amplification.
Discussion
In summary, we show here that the focal amplification of
Chromosome 8p12, one of the most frequent amplification events
in NSCLC, plays a key role in squamous cell lineage specificity of
the disease. Through the integration of genetic and gene
expression data for .330 clinical tumor specimens in conjunction
with functional cell model studies, we identified BRF2 as the target
of this amplification and a cell lineage-specific oncogene, the only
such oncogene described for lung SqCC to date. In addition, we
highlight the oncogenic potential of BRF2 for the first time and
associate its activation with increased Pol III activity, RNA
processing, and resultant cell growth potential.
The lineage-dependence model suggests that cancer cells rely on
the constitutive activation of lineage-regulating genes involved in
Figure 5. BRF2 expression in SqCC precancerous stages.
Immunostaining of 21 lung SqCC precursor lesions with anti-BRF2
polyclonal antibody revealed a monotonic increase in BRF2 expression
with increasing histopathology grade. The area within the diagnostic
area was scored as follows: 0, no positive staining; 1,25% positive cells;
2#50% positive cells; 3#75% positive cells; and 4,100% positive cells.
Each sample is represented by a single dot above its corresponding
grade with the horizontal black lines representing the median IHC score
for each grade. Red samples highlight multiple grades taken from the
same individual patient.
doi:10.1371/journal.pmed.1000315.g005
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[7]. BRF2 is unique in that it is not a prototypical lineage-specific
oncogene as no role in normal lineage development has been
established. These data suggest that lineage-specific oncogenes
may span numerous biological functions, and they are not limited
only to the established class of transcription factors (lineage
survival oncogenes) discovered to date, but also a class of genes
selected in tumorigenesis in a cell lineage-specific manner.
Recently, a candidate a lineage survival oncogene for lung AC,
TITF1 (thyroid transcription factor 1), has also been described by
numerous groups [16,58–60]. However, high-level amplification
of TITF1 and concordant increase in protein levels occur at
approximately the same frequency in both AC and SqCC (,10%–
15%, although protein levels are higher in AC overall) [61,62].
Thus, BRF2 seems to be even more specific in terms of genetic
alteration and its association with an individual subtype. Likewise,
SOX2 has been identified as a lineage survival oncogene in lung
and esophageal SqCCs [63]. Of interest, both SqCC with and
without BRF2 amplification also contains amplification of
Chromosome arm 3q targeting SOX2, suggesting that tumors
with BRF2 amplification represent a unique subset within the
larger SqCC group (Table S8). Nonetheless, our results combined
with the recent discoveries of TITF1 and SOX2 suggest that the
genes required to initiate tumorigenesis in distinct biological
contexts may shape the preferential selection of amplifications and
resulting phenotypes specific to different cancers, highlighting the
opportunity for treatment design targeting specific cell type.
Supporting Information
Figure S1 qRT-PCR analysis of BRF2 expression levels
in SqCC tumors with and without gene dosage increas-
es. BRF2 expression levels were determined for 16 SqCC tumors
withmatchingarrayCGHdatausingTaqMananalysisasdescribed
in the Methods section. Normalized BRF2 expression values were
compared between each sample and a normal lung reference to
determine the relative fold change. Raw data from these
experiments are provided in Table S4. (a) The expression for each
individual tumor is plotted along with its corresponding case
number. Samples are organized according to their BRF2 copy
number status as determined by array CGH (see Methods). The
white barsrepresenttumorswithoutcopy number increase,whereas
the crosshatched bars represent those with copy number increase.
SqCC tumors with copy number gain/amplification have higher
expression than tumors without. (b) Box plots representing the
expression of BRF2 in SqCC tumors with and without gain/
amplification. The average BRF2 expression is significantly higher
in SqCC tumors with amplification/gain than in those without
(p=0.0003, one-tailed Mann-Whitney U test), confirming the
findings from the microarray experiments detailed in the text.
Found at: doi:10.1371/journal.pmed.1000315.s001 (0.33 MB
PDF)
Figure S2 qRT-PCR analysis of BRF2 expression levels
in NSCLC cell lines. BRF2 expression levels were determined for
20 NSCLC cell lines with matching array CGH data using TaqMan
analysis as described in the Methods section. Normalized BRF2
expression values were compared between each sample and a normal
lung reference to determine the relative fold change. Raw data from
these experiments are provided in Table S5. (A) BRF2 expression
across NSCLC cell lines. Samples are organized according to their
histological subtype. The white bars represent AC cell lines, whereas
the crosshatched bars represent SqCC cell lines. The two SqCC
samples with high-level BRF2 amplification (HCC95 and H520) also
have the highest BRF2 transcript levels. (B) BRF2 expression is strongly
correlated with gene dosage. Log2 array CGH ratios for BRF2 are
plotted on the y-axis with the corresponding BRF2 mRNA expression
(as determined by qRT-PCR, described above) for each cell line
plotted on the x-axis (Pearson r=0.8645, p,0.0001).
Found at: doi:10.1371/journal.pmed.1000315.s002 (0.35 MB
DOC)
Figure S3 BRF2 knockdown reduces U6 levels in H520
cells. (A) U6 snRNA and 5S rRNA levels were determined by
Northern blot for H520 cells expressing either BRF2 targeting shRNA
(BRF2-1) or a vector control (see Methods). (B) Gel images were
analyzed with ImageJ software and the background corrected pixel
densities for U6 were normalized to 5S for each sample. The resulting
ratios are plotted relative to the control, demonstrating ,35% decrease
in U6 levels in the cell line expressing the BRF2 shRNA.
Found at: doi:10.1371/journal.pmed.1000315.s003 (0.31 MB
PDF)
Figure S4 The effect of BRF2 knockdown is specific to
SqCC cell lines with amplification. (A) BRF2 copy number
(array CGH) and (B) expression (qRT-PCR) in H520, HCC2450,
and HCC15 lung SqCC cell lines. (C) Decrease in BRF2 mRNA
levels in H520, HCC2450, and HCC15 cells expressing shRNA
targeting BRF2 (BRF2-1) relative to those expressing respective
negative vector controls (mean 6 SEM of duplicate experiments).
(D) BRF2 knockdown results in significantly decreased cell
proliferation in H520 compared to HCC2450 and HCC15 as
measured by MTT assay relative to respective vector controls
(mean 6 SEM of duplicate experiments). Values plotted are from
day 5 measurements (Methods). * p,0.05 (ANOVA).
Found at: doi:10.1371/journal.pmed.1000315.s004 (0.36 MB
PDF)
Figure S5 qRT-PCR analysis of BRF2 expression levels
in stably transduced immortalized HBEC lines. BRF2
expression levels were determined using TaqMan analysis as
described in the Methods section. Normalized BRF2 expression
values were compared between each cell line and their respective
vector controls and the corresponding fold change is plotted.
Found at: doi:10.1371/journal.pmed.1000315.s005 (0.26 MB
PDF)
Figure S6 Association of BRF2 expression and patient
survival in lung SqCC. Publically available datasets from the
Gene Expression Omnibus, (A) GSE3141 and (B) GSE4573, were
used to assess the association of BRF2 expression and patient
survival. The survival distributions of the top 40% and bottom 40%
ofsamples,on the basisofexpression of BRF2, werecompared using
a Kaplan-Meier analysis. These cutoffs (top and bottom 40%) were
picked to reflect the frequency of BRF2 copy number increase in
lung SqCC (40% of all cases). p-Values for comparing survival
distributions were calculated using the Mantel-Cox method (log-
rank test). Kaplan Meier analysis was performed using the
Mathworks MATLAB Statistics toolbox. Mantel-Cox p-values were
calculated in MATLAB using the following file: http://www.
mathworks.com/matlabcentral/fileexchange/22317-logrank.
Found at: doi:10.1371/journal.pmed.1000315.s006 (18.34 MB
PDF)
Table S1 Clinical samples used in analyses.
Found at: doi:10.1371/journal.pmed.1000315.s007 (0.04 MB
DOC)
Table S2 Regions of copy number difference on Chro-
mosome arm 8p between AC and SqCC.
Found at: doi:10.1371/journal.pmed.1000315.s008 (0.03 MB
DOC)
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Background. Lung cancer is the commonest cause of
cancer-related death. Every year, 1.3 million people die from
this disease, which is mainly caused by smoking. Most cases
of lung cancer are ‘‘non-small cell lung cancers’’ (NSCLCs).
Like all cancers, NSCLC starts when cells begin to divide
uncontrollably and to move round the body (metastasize)
because of changes (mutations) in their genes. These
mutations are often in ‘‘oncogenes,’’ genes that, when
activated, encourage cell division. Oncogenes can be
activated by mutations that alter the properties of the
proteins they encode or by mutations that increase the
amount of protein made from them, such as gene
amplification (an increase in the number of copies of a
gene). If NSCLC is diagnosed before it has spread from the
lungs (stage I disease), it can be surgically removed and
many patients with stage I NSCLC survive for more than 5
years after their diagnosis. Unfortunately, in more than half
of patients, NSCLC has metastasized before it is diagnosed.
This stage IV NSCLC can be treated with chemotherapy (toxic
chemicals that kill fast-growing cancer cells) but only 2% of
patients with stage IV lung cancer are alive 5 years after
diagnosis.
Why Was This Study Done? Traditionally, NSCLC has
been regarded as a single disease in terms of treatment.
However, emerging evidence suggests that the two major
subtypes of NSCLC—adenocarcinoma and squamous cell
carcinoma (SqCC)—respond differently to chemotherapy.
Adenocarcinoma and SqCC start in different types of lung
cell and experts think that for each cell type in the body,
specific combinations of mutations interact with the cell
type’s own unique characteristics to provide the growth and
survival advantage needed for cancer development. If this is
true, then identifying the molecular differences between
adenocarcinoma and SqCC could provide targets for more
effective therapies for these major subtypes of NSCLC.
Amplification of a chromosome region called 8p12 is very
common in NSCLC, which suggests that an oncogene that
drives lung cancer development is present in this
chromosome region. In this study, the researchers
investigate this possibility by looking for an amplified gene
in the 8p12 chromosome region that makes increased
amounts of protein in lung SqCC but not in lung
adenocarcinoma.
What Did the Researchers Do and Find? The researchers
used a technique called comparative genomic hybridization
to show that focal regions of Chromosome 8p are amplified
in about 40% of lung SqCCs, but that DNA loss in this region
is the most common alteration in lung adenocarcinomas.
Ten genes in the 8p12 chromosome region were expressed
at higher levels in the SqCC samples that they examined
than in adenocarcinoma samples, they report, and
overexpression of five of these genes correlated with
amplification of the 8p12 region in the SqCC samples. Only
one of the genes—BRF2—was more highly expressed in
squamous carcinoma cells than in normal bronchial epithelial
cells (the cell type that lines the tubes that take air into the
lungs and from which SqCC develops). Artificially induced
expression of BRF2 in bronchial epithelial cells made these
normal cells behave like tumor cells, whereas reduction of
BRF2 expression in squamous carcinoma cells made them
behave more like normal bronchial epithelial cells. Finally,
BRF2 was frequently activated in two early stages of
squamous cell carcinoma—bronchial carcinoma in situ and
dysplastic lesions.
What Do These Findings Mean? Together, these findings
show that the focal amplification of chromosome region
8p12 plays a role in the development of lung SqCC but not in
the development of lung adenocarcinoma, the other major
subtype of NSCLC. These findings identify BRF2 (which
encodes a RNA polymerase III transcription initiation factor, a
protein that is required for the synthesis of RNA molecules
that help to control cell growth) as a lung SqCC-specific
oncogene and uncover a unique mechanism for lung SqCC
development. Most importantly, these findings suggest that
genetic activation of BRF2 could be used as a marker for lung
SqCC, which might facilitate the early detection of this type
of NSCLC and that BRF2 might provide a new target for
therapy.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000315.
N The US National Cancer Institute provides detailed
information for patients and professionals about all
aspects of lung cancer, including information on non-
small cell carcinoma (in English and Spanish)
N Cancer Research UK also provides information about lung
cancer and information on how cancer starts
N MedlinePlus has links to other resources about lung cancer
(in English and Spanish)
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